Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
CG Therapeutics and University of Washington Announce Formation of Joint Monoclonal Antibody Program
April 16th, 2008
CG Therapeutics, a biotechnology company developing new cancer immunotherapies, announced that it has entered into an agreement with the University of Washington to undertake a joint monoclonal antibody development program. CG Therapeutics is commercializing CG201, a proprietary vaccine that produces antibodies that neutralize hCG, a powerful hormone produced by tumor cell to speed their growth. The new, joint program will develop human monoclonal antibodies against hCG that can be used with the CG201 vaccine to provide a comprehensive cancer treatment. The program will be headed by University of Washington researchers Drs. Karl Eric and Ingegerd Hellstrom, who are...
Source: Vaccine Weekly (2008-04-16)
|
